Ambispective Cohort Study to Evaluate the Effectiveness, Safety and Tolerance of a Doravirine-based Antirretroviral Regimen as a Switching Strategy in Virologically Supressed HIV Infected Patients: Real-world Data
Latest Information Update: 07 Nov 2023
Price :
$35 *
At a glance
- Drugs Dolutegravir (Primary) ; Doravirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 06 Dec 2021 New trial record